gsk201510196k3.htm

SECURITIES AND EXCHANGE COMMISSION 

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of 

the Securities Exchange Act of 1934

For period ending October 2015

(Name of registrant) 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices) 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F 

Form 20-F x Form 40-F 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934. 

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4R(1)(a) and (c) I give details of changes in the interests of the following Directors and Persons Discharging Managerial Responsibilities ('PDMR') who acquired American Depositary Shares ('ADSs') in GlaxoSmithKline plc ('GSK') at a price of $39.61 per ADS, following the re-investment of the dividend paid to shareholders on 1 October 2015.

Director/PDMR	ADSs
Dr M M Slaoui	1,918.567
Mr N Hirons	240.867
Mr D E Troy	1,099.657

Connected Person	ADSs
Dr K Slaoui (Connected Person to Dr M M Slaoui)	84.553

GSK was informed of these allocations on 16 October 2015.

V A Whyte

Company Secretary

19 October 2015

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised. 

Date: October 19, 2015

----------------------

Authorised Signatory for and on

behalf of GlaxoSmithKline plc